These data support a mechanism of HER3/HER2 activation and migration by ASPN in prostate cancer, thereby highlighting HER2 and HER3 as potential therapeutic vulnerabilities in metastatic prostate cancer. The gene discussed is ERBB2; the disease is prostate cancer.